Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.

Hatirnaz Ng, Özden; Eskazan, Ahmet Emre

Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.

Hatirnaz Ng, Özden; Eskazan, Ahmet Emre.

Afiliação

Hatirnaz Ng Ö; Department of Medical Biology, School of Medicine, Acibadem University, Istanbul, Turkey.
Eskazan AE; Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Fatih, Istanbul, Turkey. Electronic address: emre.eskazan@iuc.edu.tr.

Transl Oncol ; 19: 101394, 2022 May.

Article em En | MEDLINE | ID: mdl-35294914

Palavras-chave

AML; Acute myeloid leukemia; BCL2A1; FLT3; FLT3-ITD/D835; Resistance

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Transl Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google